The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1324
ISSUE 1324
November 2, 2009
Issue 1324
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Saxagliptin (Onglyza) for Type 2 Diabetes
November 2, 2009 (Issue: 1324)
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.